What are the effects of Wolff-Parkinson-White (WPW) syndrome?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 22, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

Wolff-Parkinson-White (WPW) syndrome is a heart condition that causes an extra electrical pathway between the heart's upper and lower chambers, resulting in a rapid heartbeat (tachycardia) and potentially life-threatening complications, including sudden cardiac death, particularly if atrial fibrillation develops 1.

Key Characteristics of WPW Syndrome

  • The accessory pathway, known as the Bundle of Kent, bypasses the normal electrical conduction system, allowing electrical signals to travel through the heart more quickly than normal.
  • This creates a "pre-excitation" pattern on an electrocardiogram (ECG), characterized by a shortened PR interval and a delta wave.
  • WPW can cause episodes of rapid heart rate, palpitations, dizziness, shortness of breath, and occasionally fainting.

Risks and Complications

  • In rare cases, WPW can lead to sudden cardiac death, particularly if atrial fibrillation develops, with a 10-year risk ranging from 0.15% to 0.24% 1.
  • Increased risk of sudden cardiac death is associated with a history of symptomatic tachycardia, multiple accessory pathways, and a shortest pre-excited R-R interval of <250 ms during AF 1.

Treatment Options

  • Treatment options include medication (such as beta-blockers or calcium channel blockers), cardioversion for acute episodes, and catheter ablation, which destroys the abnormal pathway and is often curative 1.
  • Ablation is recommended in patients with WPW syndrome resuscitated from sudden cardiac arrest due to AF and rapid conduction over the accessory pathway causing VF, and should be considered in patients with WPW syndrome who are symptomatic and/or who have accessory pathways with refractory periods ≤240 ms in duration 1.

From the Research

WPW Syndrome Description

  • Wolff-Parkinson-White (WPW) syndrome is a rare abnormal condition frequently associated with paroxysmal supraventricular tachycardia (PSVT) and is described as an arrhythmia under the form of increased heartbeat 2.

Effects of WPW Syndrome

  • WPW syndrome can cause increased heartbeat, leading to various symptoms and complications 2.

Treatment of WPW Syndrome

  • The management of WPW syndrome in children should begin with the use of a beta-blocker, with the addition of digoxin or procainamide for treatment failures 3.
  • For failures to conventional agents, flecainide is the preferred agent, while therapy with propafenone, amiodarone, and sotalol remains to be elucidated 3.

Associated Conditions

  • WPW syndrome can be associated with heart or inflammatory conditions, making treatment more challenging 2.

Treatment Challenges

  • The unknown causes of WPW syndrome, together with the different responses to treatment in each patient, make it difficult to establish the best therapeutic approach 2.
  • Controlled trials regarding the use of new antiarrhythmic agents are available, but the variance in dosing schemes, presence of structural heart disease, and patient age make the development of recommendations difficult 3.

Related Questions

What is the initial management for Supraventricular Tachycardia (SVT) in pediatric patients with Wolff-Parkinson-White (WPW) syndrome?
At what age is it appropriate to transition a pediatric patient with a history of neonatal Supraventricular Tachycardia (SVT) and Wolff-Parkinson-White (WPW) pattern on Electrocardiogram (ECG) from Propranolol (Propranolol) Three Times a Day (TID) to Metoprolol (Metoprolol) Twice a Day (BID) for simplified dosing?
What medication should be given to a patient with Wolff-Parkinson-White (WPW) syndrome and atrial fibrillation (Afib) presenting with tachycardia who is stable?
What are the first-line treatments for Atrial Fibrillation (AF) with Wolff-Parkinson-White (WPW) syndrome, AF post-cardiac surgery, AF in Heart Failure (HF) with reduced Ejection Fraction (EF), and AF in thyrotoxicosis?
What medications are contraindicated in Wolff-Parkinson-White (WPW) syndrome?
What is the effect of infrared light on psoriasis?
What treatment is recommended for a 60-year-old male with elevated Lipoprotein(a) (Lp(a)) of 185, Apolipoprotein B (Apo B) of 115, High-Density Lipoprotein (HDL) of 60, and Low-Density Lipoprotein (LDL) of 132, with a Coronary Artery Calcium (CAC) score of 0?
What is a hearing conservation program (HCP)?
Does early propping up to walk increase the risk of genu varum (bowlegging) in infants?
What are the implications of a history of multiple concussions with loss of consciousness (LOC)?
What are the alternatives to Sitagliptin (Sitagliptin phosphate), a dipeptidyl peptidase-4 (DPP-4) inhibitor?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.